End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.99 CNY | -5.96% | -0.11% | -14.05% |
May. 24 | Wall Street Cues, Property Woes, Central Banks Curb Asian Stock Markets | MT |
May. 24 | Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.82 for the current year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Real Estate Development & Operations
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.05% | 13.74B | B+ | ||
-2.42% | 24.63B | A- | ||
+12.29% | 11.3B | - | B- | |
-25.65% | 7.67B | - | B+ | |
-7.87% | 6.8B | C- | ||
+0.78% | 6.57B | C+ | ||
+0.63% | 6.42B | A- | ||
-1.11% | 3.73B | C | ||
+40.72% | 3.52B | B+ | ||
+7.34% | 3.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000002 Stock
- Ratings China Vanke Co., Ltd.